High resolution photopolymer for 3D printing of personalised microneedle for transdermal delivery of anti-wrinkle small peptide.

Lim SH, Kathuria H, Amir MHB, Zhang X, Duong HTT, Ho PC, Kang L

Journal of controlled release : official journal of the Controlled Release Society15 Oct 2020Cited by 73 (Europe PMC)

PMID33068646DOI10.1016/j.jconrel.2020.10.021PepBankPUB-33068646

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Argireline (acetyl hexapeptide-8) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Argireline (acetyl hexapeptide-8).

01LabNot a test of Argireline (acetyl hexapeptide-8) aloneEx vivo tissueActivity measurement
In laboratory tests, the fabricated AHP-3 delivery microneedle patch penetrated human cadaver dermatomed skin.
In plain wordsIn lab tests, the peptide delivery patch penetrated skin from human cadavers.
Peptide
Argireline (acetyl hexapeptide-8)
Outcome
Not applicableSkin penetration
Study
humann: not reported in source
human cadaver dermatomed skin
Outcome group
Pharmacokinetics · Pharmacology
Source sentences
Summary
In vitro characterisation of fabricated MN patch demonstrated the ability to penetrate human cadaver dermatomed skin and the MN remained intact after compression.
In this study, Argireline (acetyl hexapeptide-8) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Argireline (acetyl hexapeptide-8).
Report a problemFND-3306864603
02LabNot a test of Argireline (acetyl hexapeptide-8) aloneIn vitro (cells)Safety outcome
In human dermal fibroblasts, the final delivery polymer showed minimal cytotoxicity.
In plain wordsIn cells, the final delivery polymer showed minimal toxicity.
Peptide
Argireline (acetyl hexapeptide-8)
Outcome
Not applicablePolymer cytotoxicity
Study
humann: not reported in source
human dermal fibroblasts
Outcome group
Adverse events · Pharmacology
Source sentences
Summary
The final polymer also had minimal cytotoxicity to human dermal fibroblast.
In this study, Argireline (acetyl hexapeptide-8) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Argireline (acetyl hexapeptide-8).
Report a problemFND-3306864605
03LabNot a test of Argireline (acetyl hexapeptide-8) aloneIn vitro (cell-free)Activity measurement
In fabrication tests, AHP-3 remained stable during loading into the optimal resin.
In plain wordsIn lab tests, AHP-3 remained stable during resin fabrication.
Peptide
Argireline (acetyl hexapeptide-8)
Outcome
No significant changePeptide stability during fabrication
Study
n: not reported in source
AHP-3-loaded photopolymer
Outcome group
Pharmacokinetics · Pharmacology
Source sentences
Summary
Drug loading into the optimal resin demonstrated that AHP-3 remained stable throughout the fabrication process and there was no effect on the physical properties of final polymer.
In this study, Argireline (acetyl hexapeptide-8) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Argireline (acetyl hexapeptide-8).
Report a problemFND-3306864601
04LabNot a test of Argireline (acetyl hexapeptide-8) aloneIn vitro (cell-free)Activity measurement
In fabrication tests, AHP-3 loading did not alter the final polymer's physical properties.
In plain wordsIn lab tests, AHP-3 loading did not change the polymer's physical properties.
Peptide
Argireline (acetyl hexapeptide-8)
Outcome
No significant changePolymer physical properties
Study
n: not reported in source
AHP-3-loaded photopolymer
Outcome group
Pharmacokinetics · Pharmacology
Source sentences
Summary
Drug loading into the optimal resin demonstrated that AHP-3 remained stable throughout the fabrication process and there was no effect on the physical properties of final polymer.
In this study, Argireline (acetyl hexapeptide-8) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Argireline (acetyl hexapeptide-8).
Report a problemFND-3306864602
05LabNot a test of Argireline (acetyl hexapeptide-8) aloneIn vitro (cell-free)Activity measurement
In laboratory tests, the fabricated AHP-3 delivery microneedles remained intact after compression.
In plain wordsIn lab tests, the peptide delivery microneedles remained intact after compression.
Peptide
Argireline (acetyl hexapeptide-8)
Outcome
No significant changeMicroneedle integrity after compression
Study
n: not reported in source
AHP-3-loaded photopolymer
Outcome group
Pharmacokinetics · Pharmacology
Source sentences
Summary
In vitro characterisation of fabricated MN patch demonstrated the ability to penetrate human cadaver dermatomed skin and the MN remained intact after compression.
In this study, Argireline (acetyl hexapeptide-8) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Argireline (acetyl hexapeptide-8).
Report a problemFND-3306864604

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.